Dolomite Bio, a brand of Blacktrace Holdings Limited, celebrated the first anniversary of its launch on March 1st, marking the end of a fruitful year in business. This biology-focused brand, a spin out from sister company Dolomite Microfluidics, is dedicated to the development of innovative products for high throughput single cell encapsulation.
Dolomite Bio has launched a new Injection Valve and Sample Loop for single cell RNA sequencing workflows. This option enables straightforward, gentle introduction of evenly distributed mRNA capture beads into the company’s RNA-Seq System for individual encapsulation of cells.
Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer. Karolina Nowakowska, a PhD student at The Institute of Cancer Research, explained: “Our team is focused on studying treatment resistance in prostate cancer patients, looking at the biochemical mechanisms responsible.
Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at the single cell level.
Dolomite Bio has developed the Single Cell RNA-Seq System for efficient, high throughput single cell transcriptomics. This compact, scalable system enables rapid, reproducible droplet encapsulation of individual cells, allowing up to 10,000 single cell libraries to be generated in one 15-minute run.